FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914389504> ?p ?o ?g. }

• W2914389504 endingPage "585" @default.
• W2914389504 startingPage "585" @default.
• W2914389504 abstract "585 Background: Several previous reports indicated that cetuximab (Cmab) rechallenge may be efficacious in some patients for whom Cmab was previously effective. Liquid biopsy can detect the some emerging mutations for resistance with Cmab. Considering the plasticity and elasticity of sensitive clone, we assumed we could identify the patients with benefit from Cmab rechallenge by liquid biopsy. This current study investigates the predictability of efficacy for Cmab rechallenge by liquid biopsy in the E-Rechallenge Trial. Methods: The E-Rechallenge Trial is a multicenter phase II study in mCRC patients who have become refractory to fluoropyrimidines, L-OHP, CPT-11, Cmab, and bevacizumab, and in whom previous treatment with Cmab was effective in any earlier line (achieving CR, PR, or SD that persisted for ≥ 6 months). The other main eligibility criteria are; RAS wild type, measurable disease, aEFI ≥ 16 weeks between the last dose of Cmab during previous treatment and the start of Cmab rechallenge. Protocol treatment is the combination of weekly Cmab with biweekly CPT-11. Additional research of ctDNA was conducted optionally. Baseline plasma samples were analyzed for KRAS, NRAS, BRAF and EGFR S492R mutations using digital PCR (LBx probe, RIKEN GENESIS). A cut-off of the mutation allele frequency was > 0.1%. Results: Between Dec. 2014 and Oct. 2017, 33 patients were enrolled. The primary endpoint; the rates of PR/SD/PD were PR 15.6%/SD 40.6%/PD 43.8%. Twenty-four of 33 patients participated in the additional research. In the additional cohort, the rates of PR/SD/PD were PR 12.5%/SD 50.0%/PD 37.5%. The mutations were detected at the baseline of Cmab rechallenge as followings; KRAS exon 2 29.2%, exon 3,4 33.3%, BRAF V600E 12.5%, EGFR S492R 12.5%. In wild type of these genes the PR and SD rate increased to 25% and 50%, respectively. Conclusions: Cmab rechallenge showed some activity in the salvage setting, in patients for whom Cmab was previously effective. KRAS, BRAF, and EGFR S492R screening by liquid biopsy may contribute to identify patients with benefit from Cmab rechallenge. The additional data of ctDNA may be provided in the conference. Clinical trial information: UMIN 000016439." @default.
• W2914389504 created "2019-02-21" @default.
• W2914389504 creator A5001002762 @default.
• W2914389504 creator A5002562596 @default.
• W2914389504 creator A5005359544 @default.
• W2914389504 creator A5007757700 @default.
• W2914389504 creator A5016814013 @default.
• W2914389504 creator A5023562460 @default.
• W2914389504 creator A5024247368 @default.
• W2914389504 creator A5032930623 @default.
• W2914389504 creator A5045819149 @default.
• W2914389504 creator A5047839722 @default.
• W2914389504 creator A5054543898 @default.
• W2914389504 creator A5059536976 @default.
• W2914389504 creator A5069216523 @default.
• W2914389504 creator A5072005132 @default.
• W2914389504 creator A5073795248 @default.
• W2914389504 creator A5090955736 @default.
• W2914389504 date "2019-02-01" @default.
• W2914389504 modified "2023-10-03" @default.
• W2914389504 title "Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial." @default.
• W2914389504 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.585" @default.
• W2914389504 hasPublicationYear "2019" @default.
• W2914389504 type Work @default.
• W2914389504 sameAs 2914389504 @default.
• W2914389504 citedByCount "5" @default.
• W2914389504 countsByYear W29143895042021 @default.
• W2914389504 countsByYear W29143895042022 @default.
• W2914389504 countsByYear W29143895042023 @default.
• W2914389504 crossrefType "journal-article" @default.
• W2914389504 hasAuthorship W2914389504A5001002762 @default.
• W2914389504 hasAuthorship W2914389504A5002562596 @default.
• W2914389504 hasAuthorship W2914389504A5005359544 @default.
• W2914389504 hasAuthorship W2914389504A5007757700 @default.
• W2914389504 hasAuthorship W2914389504A5016814013 @default.
• W2914389504 hasAuthorship W2914389504A5023562460 @default.
• W2914389504 hasAuthorship W2914389504A5024247368 @default.
• W2914389504 hasAuthorship W2914389504A5032930623 @default.
• W2914389504 hasAuthorship W2914389504A5045819149 @default.
• W2914389504 hasAuthorship W2914389504A5047839722 @default.
• W2914389504 hasAuthorship W2914389504A5054543898 @default.
• W2914389504 hasAuthorship W2914389504A5059536976 @default.
• W2914389504 hasAuthorship W2914389504A5069216523 @default.
• W2914389504 hasAuthorship W2914389504A5072005132 @default.
• W2914389504 hasAuthorship W2914389504A5073795248 @default.
• W2914389504 hasAuthorship W2914389504A5090955736 @default.
• W2914389504 hasConcept C121608353 @default.
• W2914389504 hasConcept C126322002 @default.
• W2914389504 hasConcept C143998085 @default.
• W2914389504 hasConcept C203092338 @default.
• W2914389504 hasConcept C2775934546 @default.
• W2914389504 hasConcept C2776694085 @default.
• W2914389504 hasConcept C2777802072 @default.
• W2914389504 hasConcept C2779998722 @default.
• W2914389504 hasConcept C2781187634 @default.
• W2914389504 hasConcept C526805850 @default.
• W2914389504 hasConcept C535046627 @default.
• W2914389504 hasConcept C71924100 @default.
• W2914389504 hasConceptScore W2914389504C121608353 @default.
• W2914389504 hasConceptScore W2914389504C126322002 @default.
• W2914389504 hasConceptScore W2914389504C143998085 @default.
• W2914389504 hasConceptScore W2914389504C203092338 @default.
• W2914389504 hasConceptScore W2914389504C2775934546 @default.
• W2914389504 hasConceptScore W2914389504C2776694085 @default.
• W2914389504 hasConceptScore W2914389504C2777802072 @default.
• W2914389504 hasConceptScore W2914389504C2779998722 @default.
• W2914389504 hasConceptScore W2914389504C2781187634 @default.
• W2914389504 hasConceptScore W2914389504C526805850 @default.
• W2914389504 hasConceptScore W2914389504C535046627 @default.
• W2914389504 hasConceptScore W2914389504C71924100 @default.
• W2914389504 hasIssue "4_suppl" @default.
• W2914389504 hasLocation W29143895041 @default.
• W2914389504 hasOpenAccess W2914389504 @default.
• W2914389504 hasPrimaryLocation W29143895041 @default.
• W2914389504 hasRelatedWork W1963973664 @default.
• W2914389504 hasRelatedWork W2051540233 @default.
• W2914389504 hasRelatedWork W2171311886 @default.
• W2914389504 hasRelatedWork W2369149866 @default.
• W2914389504 hasRelatedWork W2563870823 @default.
• W2914389504 hasRelatedWork W2599866838 @default.
• W2914389504 hasRelatedWork W2617055067 @default.
• W2914389504 hasRelatedWork W2729289325 @default.
• W2914389504 hasRelatedWork W2784706285 @default.
• W2914389504 hasRelatedWork W2946290469 @default.
• W2914389504 hasVolume "37" @default.
• W2914389504 isParatext "false" @default.
• W2914389504 isRetracted "false" @default.
• W2914389504 magId "2914389504" @default.
• W2914389504 workType "article" @default.